![Fig. 1. Protocols for immediate pretreatment (A ); delayed pretreatment (B ); immediate pretreatment in the presence of the adenosine triphosphate–sensitive potassium (KATP) inhibitors glybenclamide (10 μm), 5-hydroxydecanoate (5-HD, 100 μm), or 1-[5-[2-(5-chloro-o-anisamido)ethyl]-2-methoxyphenyl]sulfonyl-3-methylthiourea (HMR-1098 100 μm) (C ); and delayed pretreatment in presence of KATP-inhibitors (D ). ISO = isoflurane; LDH = lactate dehydrogenase.](https://asa2.silverchair-cdn.com/asa2/content_public/journal/anesthesiology/99/4/10.1097_00000542-200310000-00023/2/23ff1.png?Expires=1716507293&Signature=tBNmworPJAr1hyiDckO1QVYLX-LKIpBjxAcqJg2F2ILh-XrwI68skb3ZiPfCQ50fJlGTV-w12iY3l7l09PxacIylFzR6SBNSJ3RItpUlywGcAso0Sqihpm2H-Za4Lndi87brnwAa3fxcui7WPTmq~~45rRIo5e8jTxfsHn4xDenNepIW8LQFMbgoXOwigU0frCkXgbOaOB-AUsDzE7jDDpIeuFst5T0oEFGQDQFUkwNYGYTfrEAB7kNND2s8fNphO~CTiozpXAtmHTDx7bQIZp4iLasvt5HwH-KajLcIYdDBjEwhMmDPOPVOx6lzdPtQ-cFLfZ8OD9sPbh5CUOdWFQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Fig. 1. Protocols for immediate pretreatment (A ); delayed pretreatment (B ); immediate pretreatment in the presence of the adenosine triphosphate–sensitive potassium (KATP) inhibitors glybenclamide (10 μm), 5-hydroxydecanoate (5-HD, 100 μm), or 1-[5-[2-(5-chloro-o-anisamido)ethyl]-2-methoxyphenyl]sulfonyl-3-methylthiourea (HMR-1098 100 μm) (C ); and delayed pretreatment in presence of KATP-inhibitors (D ). ISO = isoflurane; LDH = lactate dehydrogenase.
